Filing Flows

Filing Flows › Companies › Crescent Biopharma › Cash flow

Crescent Biopharma cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$19.5M in Q2 2026 · −$73.6M over twelve months

Operating cash flow−$19.5M
Capital spending−$13K
Free cash flow−$19.5M

Analysis

In Q2 2026, Crescent Biopharma generated −$19.5M of operating cash flow and spent $13K on capital projects, leaving free cash flow of −$19.5M. That is $2.9M less than in Q2 2025 (−$16.5M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$72.7M; the largest uses were other investing ($78.2M), operating cash flow ($72.7M), capital spending ($939K); besides operations, cash came from other financing ($171M); the cash balance rose by $18.9M.

Operating cash flow was −$19.5M against net income of −$24.8M. The largest differences: stock-based pay +$4.0M, accrued liabilities +$3.0M, prepaid and other assets −$1.0M.

Free cash flow

Crescent Biopharma: free cash flow by quarterCrescent Biopharma: free cash flow by quarter−$8.0MQ3 2024−$6.3MQ4 2024−$10.9MQ1 2025−$16.5MQ2 2025−$18.1MQ3 2025−$26.9MQ4 2025−$9.1MQ1 2026−$19.5MQ2 2026
Operating cash flow less capital spending.
Crescent Biopharma: operating cash flow against capital spendingCrescent Biopharma: operating cash flow against capital spendingOperating cash flowCapital spending−$8.0M$0Q3 2024−$6.3M$0Q4 2024−$10.9M$0Q1 2025−$16.4M$140KQ2 2025−$17.5M$586KQ3 2025−$26.7M$193KQ4 2025−$8.9M$147KQ1 2026−$19.5M$13KQ2 2026
Latest (Q2 2026): Operating cash flow −$19.5M, Capital spending $13K.

Capital allocation, year by year

Crescent Biopharma: where the cash came from (up) and went (down), by fiscal yearCrescent Biopharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedAsset salesCapital spendingFY2021: Operating cash flow −$57.5MFY2021: Shares issued $10.7MFY2021: Capital spending −$15K$10.7MFY2021FY2022: Operating cash flow −$46.5MFY2022: Shares issued $4.2MFY2022: Capital spending −$84K$4.2MFY2022FY2023: Operating cash flow −$34.9MFY2023: Shares issued $28.8MFY2023: Capital spending −$21K$28.8MFY2023FY2024: Operating cash flow −$31.1MFY2024: Shares issued $5KFY2024: Asset sales $30KFY2024: Capital spending −$10K$35KFY2024FY2025: Operating cash flow −$71.5MFY2025: Shares issued $5KFY2025: Capital spending −$919K$5KFY2025
Over these 5 years operating cash flow totalled −$241M; the largest uses were operating cash flow ($241M) and capital spending ($1.0M). Cash-flow statements as filed.

Where the cash came from and went

Crescent Biopharma: sources (+) and uses (−) of cash, Q2 2026Crescent Biopharma: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$19.5MCash drawn (+) / kept (−)$17.6MOther investing$1.8MOther financing$136KCapital spending−$13K
Crescent Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Crescent Biopharma: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$171MOther investing−$78.2MOperating cash flow−$72.7MCash drawn (+) / kept (−)−$18.9MCapital spending−$939K

From profit to cash

Crescent Biopharma: net income to operating cash flow, Q2 2026Crescent Biopharma: net income to operating cash flow, Q2 2026Net income−$24.8MDepreciation & amortization$66KStock-based pay$4.0MAccrued liabilities$3.0MPrepaid and other assets−$1.0MOperating cash flow−$19.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$19.5M−$13K—$17.6M−$19.5M
Q1 2026−$8.9M−$147K—$24.0M−$9.1M
Q4 2025−$26.7M−$193K—−$79.9M−$26.9M
Q3 2025−$17.5M−$586K—$19.4M−$18.1M
Q2 2025−$16.4M−$140K—−$130M−$16.5M
Q1 2025−$10.9M—$5K$12.3M−$10.9M
Q4 2024−$6.3M——−$34.8M−$6.3M
Q3 2024−$8.0M——$8.0M−$8.0M

Crescent Biopharma: income statement and cash flow

Crescent Biopharma, Q1 2026: revenue $1.0M. The chart follows the revenue to costs, profit and cash.

Crescent Biopharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.